The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information WR227825 is an antimalarial pyrroloquinazolinediamine derivative with high potency but a low therapeutic index. A series of carbamate, carboxamide, succinimide, and alkylamine derivatives of WR 227825 were prepared to search for compounds with an improved therapeutic index. The new acetamides and imide showed potent cell growth inhibition against four clones of Plasmodium falciparum (D-6, RCS, W-2 and TM91C235), with a 50% inhibitory concentration of approx. 0.01 ng/ml, and were highly active against Plasmodium berghei, with 100% cure at doses from <0.1 mg/kg of body weight to 220 mg/kg. The carbamates and alkyl derivatives, however, showed weak activity against Plasmodium falciparum cell growth but were highly efficacious in tests against P. berghei by the Thompson test. WR227825 is an antimalarial pyrroloquinazolinediamine derivative with a high potency but a low therapeutic index. A series of carbamate, carboxamide, succinimide, and alkylamine derivatives of WR227825 were prepared to search for compounds with an improved therapeutic index. The new acetamides and imide showed potent cell growth inhibition against four clones of Plasmodium falciparum (D-6, RCS, W-2, and TM91C235), with a 50% inhibitory concentration of -0.01 ng/ml, and were highly active against Plasmodium berghei, with 100% cure at doses from <0.1 mg/kg of body weight to 220 mg/kg. The carbamates and alkyl derivatives, however, showed weak activity against Plasmodium falciparum cell growth but were highly efficacious in tests against P. berghei by the Thompson test. The best compounds, bis-ethylcarbamate (compound 2a) and tetraacetamide (3a) derivatives, further demonstrated high potency against the sporozoite Plasmodium yoelii in mice and P. falciparum and Plasmodium vivax in aotus monkeys. Against the AMRU-1 strain of P. vivax, which has four dihydrofolate reductase mutations and is highly resistant to antifolates, tetra-acetamide 3a cured the monkeys at doses of 1 and 3 mg/kg. Compound 2a cured only one out of two monkeys at 3 mg/kg. The results indicated that the new derivatives 2a and 3a not only have retained/improved the antimalarial efficacy of the parent compound WR227825 but also were less toxic to the animals used in the tests.
Malaria is one of the most common diseases in countries of 20 mg/kg, and produced deaths in aotus monkeys at doses less Africa, Southeast Asia, and South America (12, 27, 28, 31, 32) .
than 2 mg/kg (33). The PQZ was demonstrated to be an antifolate The increasing prevalence of multiple-drug-resistant strains of (15). The low therapeutic index of compound 1 has severely Plasmodium falciparum in most areas where malaria is enlimited its value as an antimalarial agent. Nevertheless, the high demic has significantly reduced the efficacy of current antimaefficacy and low therapeutic index of WR227825 make it a challarial drugs for the prophylaxis and treatment of this disease lenging lead compound for optimizing the fabrication of new (17, 19) . Furthermore, the usefulness of many newer antimaderivatives with improvement in their therapeutic index or pharlarial drugs was impaired by their side effects. Lethal hemolysis macological profiles. In addition to its high host toxicity, the lead side effects were observed in glucose-6-phosphate dehydrogecompound 1 is sparingly soluble in common organic solvents and nase-deficient recipients of 8-aminoquinoline drugs (2, 3), water, a highly undesirable physical property for large-scale synnamely, primaquine and tafenoquine. Central nervous system thesis and purification ( Fig. 1 ). toxicity was a problematic side effect in the patients treated To overcome the toxicity and solubility problems of the lead with mefloquine (22, 24) . Therefore, there is an eminent need molecule, a series of WR227825 derivatives were prepared in for new and safe antimalarial drugs to combat this disease in this study, wherein the amino groups at positions 1 and 3 were areas of malaria endemicity.
substituted to render the new carbamate, carboxamide, succinPyrroloquinazolinediamine (PQZ) derivatives were reported imide, or alkyamine derivatives. The antimalarial efficacy of all to possess anticancer, antimicrobial, and antimalarial activities new derivatives was first assessed in vitro against four clones of (13). Among the PQZ derivatives, WR227825 (compound 1) is P. falciparum, D-6, RCS, W-2, and TM91C235, followed by the one of the most potent antimalarial agents ever reported (26).
Thompson test against P. berghei in mice. Based on the preThis compound not only displayed high in vitro efficacy against P.
liminary test results, two of the most promising compounds, 2a falciparum, with a 50% inhibitory concentration (IC 50 ) of -0. 01 and 3a, were further tested in aotus monkeys against P. falcing/ml, but was also highly active against Plasmodium berghei in a parum and P. vivax, the latter of which is highly resistant to rodent model, with a 100% curative oral dose of <1 to 20 mg/kg antifolates. Chemical synthesis and antimalarial activities of of body weight. However, WR227825 also exhibited high host these new derivatives are discussed in this report. toxicity, with a subcutaneous 50% lethal dose in mice at less than (7) and Chulay et al. (4) . Four P. falciparum malaria parasite clones from the CDC (Indochina III, W-2; Sierra Leone I, D-6), Southeast Asia (TM91C235), and Brazil (RCS) were utilized in and the drug concentration of the suspension. In general, the volume is given at susceptibility testing. They were derived by direct visualization and micromanip-0.01 ml/gram of body weight. ulation from patient isolates (20) . The W-2 clone is susceptible to mefloquine but Five mice were used in each dosage group. Blood films were taken on day 6 resistant to chloroquine, sulfadoxine, pyrimethamine, and quinine, whereas the and biweekly for 31 days. Mice that were blood film negative on day 31 postin-D-6 clone is naturally resistant to mefloquine but susceptible to chloroquine, fection were considered cured. Compounds were considered active when the sulfadoxine, pyrimethamine, and quinine. TM91C235 and RCS are multiplesurvival time of the treated mice was greater than twice that of the control mice drug resistance P. falciparum isolates from Southeast Asia and Brazil, respec-(i.e., 12 to 14 days). Mice losing >20% of their body weight were sacrificed. The tively. Test compounds were initially dissolved in dimethyl sulfoxide and diluted test results are shown in Table 2 . 400-fold in RPMI 1640 culture medium supplemented with 25 mM HEPES, 32 (iii) Sporozoite induction test. Mice are inoculated in their intraperitoneal mM NaHCO 3 , and 10% Albumax I (Gibco BRL, Grand Island, NY). These cavities with 250,000 sporozoites of Plasmodium yoelii on day 0. Blood examinasolutions were subsequently serially diluted twofold with a Biomek 1000 appations and weights are taken at frequent intervals, at least twice a week. The days ratus (Beckman, Fullerton, CA) over 11 different concentrations. The parasites of examination relative to day 0 vary to avoid weekend work. This sporozoite were exposed to serial dilutions of each compound for 48 h and incubated at 37°C induction test (5, 25) is run for a minimum of 31 days. All mice alive on the last with 5% 02, 5% CO 2 , and 90% N 2 prior to the addition of [ 3 H]hypoxanthine. day with negative blood films are considered cured. Mice losing >20% of their After a further incubation of 18 h, parasite DNA was harvested from each body weight at any time are sacrificed. microtiter well using a Packard Filtermate 196 harvester (Meriden, CT) onto Infected, nontreated negative controls are included in every experiment to glass filters. The uptake of [ 3 Hjhypoxanthine was measured with a Packard validate the infectivity of the sporozoites. While these sporozoites usually proTopCount scintillation counter. Concentration-response data were analyzed by a duce patent infections, a small number of mice remain blood negative. Caution nonlinear regression logistic dose-response model, and the IC 5 s values for each must be taken when judging a compound as prophylactic when the patency rate compound were calculated. The results are shown in Table 1. in the negative controls is less than 100%. (ii) In vivo antimalarial studies of P. berghei in mice. The in vivo efficacies of Positive control groups are included occasionally, and they are treated with the new compounds were determined by a modified Thompson test (1) . This test either primaquine or tafenoquine.
measures the survivability of mice and parasite clearance following administraRoutinely, 20,000 red blood cells are examined in a thin blood film before an tion of the drug on days 3 to 5 postinfection. In brief, 5 X 10' P. berghei-infected animal is judged negative. The sensitivity of this technique is 0.01% infected red erythrocytes (KBG-173 strain) were inoculated into the intraperitoneal cavity of blood cells. Each compound was ground with a mortar and pestle and suspended male mice that weighed 24 to 30 g. By day 3 postinfection, parasitemia ranged in 0.5% hydroxyethylcellulose and 0.1% Tween 80 for compounds to be adminfrom 1.0 to 3.7%. Each drug, suspended in 0.5% hydroxyethylcellulose-0.1% istered p.o., and those given subcutaneously (s.c.) were suspended in peanut oil. Tween 80, was administered orally (p.o.) once daily from days 3 to 5 postinfecEach compound was prepared at three different dose levels. tion. The volume of drug suspension given depends on the weight of the mouse Four-week-old male CD-1 mice, purchased from Charles River and weighing about 16 to 17 g, were placed five per cage and allowed to acclimate for 4 days before being treated and then inoculated with sporozoites. They were fed food and water ad lib and maintained at 24°C with 12 h of light and 12 h of darkness. The cages and water bottles were changed biweekly. The mice were weighed on H 2 N[N N. Plasmodium yoelii (17XNL) was used to infect mice that would be used to N-CH 2 /R C-t 2 / infect the mosquitoes. Compounds were administered once a day for three NH 2 consecutive days, either p.o. or s.c., to mice on the day before (day -1), 4 h before (day 0), and the day after (day 1) the inoculation of sporozoites into the intraperitoneal cavity with 2.5 x 101 sporozoites of P. yoelii on day 0. Whole-body 2a (CH3CH 2 OC=O)NH-(CH 3 CH 2 OC=O)NHweights were taken on day 0 and day 6 and then twice a week for 31 days. A blood film was taken on day 6 and then twice a week for 31 days. Mice losing more than 2b (CH 3 CH 2 OC=O)NH-(CH 3 CH 2 OC=O) 2 Nabout 20% of their body weight were sacrificed. All mice alive on day 31 with no 3a (CH 3 C=O) 2 N-(CH 3 C=O) 2 Nparasites in a blood film were considered cured. A compound was considered 3b (CH3C=O)NH-(CH 3 C=O) 2 Nactive against either the sporozoite or the exoerythrocytic stage if no parasites were found in the blood films taken on day 6 or in subsequent blood films taken 0 weekly for 31 days. A compound was considered to exhibit marginal activity if 3c
FN-kN-
only low levels of parasites were found (less than about 10%) in blood films taken on day 6 or in any blood films taken biweekly for 31 days. Mice alive on day 31 0 0 with no parasites found in any blood films were considered cured. 4 NH 2 -HO-(iv) Antimalarial activity against P.falciparum in aotus monkey. Six malaria-
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(CHCH 2 ) 2 N-(CH3CH 2 ) 2 Nnaive Autus lemurinus (male and female; 787 to 978 g) monkeys of karyotypes VIII and IX (14) were housed at the Gorgas Memorial Institute in Panama and FIG. 2. Chemical structures of pyrroloquinazolinediamine decared for and maintained as described by Obaldia (18). They were divided into rivatives.
two groups of two Aotus monkeys each plus two controls and infected with ANTIMICROB. AGENTS CHEMOTHER. and 3a, were further tested against P. falciparum and P. vivax antimalarial activity against P. berghei (Table 2 ) but also were determination were collected at the following time points: day 0 (CBC and highly potent in vitro against four clones of P. falciparum, with chemistry panel [alanine aminotransferase, creatinine, and BUN]) and day 4 an IC 5 o of <0.02 ng/ml (Table 1 ). In the Thompson test, (CBC and chemistry panel). CBC and chemistry panels were done the day prior compound 3a produced a 100% cure of mice in all dose groups to the first dose and 24 h after the last dose and at weekly intervals thereafter.
from 0.625 to 220 mg/kg but exhibited delayed toxicity to all mice at 330 and 440 mg/kg (deaths on days 12 to 16). Coin-RESULTS pound 3b, though less active than compound 3a, cured more Antimalarial assessment. A series of carbamate, acetthan half (three out of five) of the mice in the low-dose (0.625 amide, succinimide, and alkyl derivatives of WR227825 and mg/kg) groups. Succinimide 3c showed good cell growth inhibition in all body weight were observed. CBC parameters remained within four cell lines, with an IC 50 equal to or better than that of the normal ranges. A steady decrease of the hepatic enzyme serum parent drug (compound 1). However, in the Thompson test, glutamic-pyruvic transaminase from 75.3 to 17.7 units and a compound 3c showed only moderate activity, with no cures in decrease of BUN from 24.35 to <10.00 units were observed in the groups treated with doses of 10 or 40 mg/kg. At a higher one monkey during the observation period. However, the mondose of 80 mg/kg, two out of five mice showed early death on key did not present any gastrointestinal or renal abnormal days 8 and 9, indicating host toxicity at this high-dose level, symptoms, although these parameters are indicative of a deBoth 1-hydroxy analog 4 and tetraethyl derivative 5 were crease in hepatic function. more than 1,000-fold less active than the lead compound WR227825 in an in vitro test against the cell growth of DISCUSSION P. falciparum isolates (Table 1) yet were highly potent against P. berghei in a mouse test (Table 2) . Compound 4 cured five out
The antimalarial efficacies of the new compounds were evalof five mice in doses from 80 to 160 mg/kg. Deaths due to uated against the cell growth of four P. falciparum isolates, toxicity were observed at a higher dose level of 320 mg/kg. D-6, W-2, RCS, and TM91C235, and by the Thompson test Tetraethyl derivative 5 produced 100% cure at doses ranging against P. berghei. Two of the compounds, 2a and 3a, were from 10 to 80 mg/kg. Host toxicity became obvious at the tested further in aotus monkey against P. falciparum and higher dose of 160 mg/kg, killing four out of eight mice. Coin-P. vivax. The structure-activity relationship studies indicated pound 5 was tested in a separate experiment using eight inthat carbamylation or alkylation of WR227825 (compounds 2a, stead of five mice per dose group. 2b, and 5) resulted in a dramatic reduction in cell growth During testing against P. falciparum in aotus monkeys, both inhibition against clones of P. falciparum from several huncompounds 2a and 3a cleared parasitemia by day 3 at an oral dredfold to more than 1,000-fold. Conversion of the 3-amino dose of 1 mg/kg, and no recrudescence was observed for >100 group to hydroxy analog 4 likewise decreased the in vitro days. Against P. vivax, which has four dihydrofolate reductase antimalarial activity. In contrast, acetamide and succinimide (DHFR) mutations and is highly resistant to antifolates, such derivatives (compounds 3a, 3b, and 3c) retained or increased as pyrimethamine and cycloguanil, compound 3a cured aotus the cell growth inhibitory activity in all four isolates of P. monkeys at 1 and 3 mg/kg/day p.o for 3 days. Compound 2a falciparum, D-6, W-2, RCS, and TM91C235. Nevertheless, all was, however, less active at the same doses, with only one out five classes of derivatives prepared in this study exhibited of two monkeys cured at 3 mg/kg and none cured at 0.5 and strong antimalarial activity in the Thompson test against P. 1 mg/kg (Table 3) .
berghei (Table 2) . Ethyl carbamates 2a and 2b cured five out of Against P. yoelii in sporozoite-challenged mice, compound five mice treated with doses from 2.5 mg/kg to 80 mg/kg. 3a completely prevented the development of parasitemia at Acetamide derivative 3a cured 100% of mice groups treated doses ranging from 0.65 to 40 mg/kg for 3 days by oral adminwith doses ranging from 0.625 to 220 mg/kg. Toxicity was found istration (Table 4) . In this test, tafenoquine (21, 29, 30) , a new at doses of 330 and 440 mg/kg. Succinimide 3c, although it malaria prophylactic drug, was used as a positive control. Coinshowed potent in vitro activity, is the least active in the Thomppound 3a showed 100% protection of the mice at a dosage son test against P. berghei among the compounds studied, sugas low as 0.625 mg/kg compared to a dosage of 5 mg/kg for gesting a bioavailability problem of oral administration. Furtafenoquine in the same test.
ther structure-activity relationship studies led to the synthesis Preliminary toxicological studies in aotus monkeys were carof 1-hydroxy-3-amino analog of WR227825, compound 4, an ried out using the same species of monkeys as in the efficacy analog of compound 1 with the 1-amino group replaced with a studies. Two monkeys were used per group. The results indihydroxy group. As expected, compound 4 showed no inhibitory cated that no changes in behavior, weight, or blood chemistry activity against cell growth in an in vitro test, since both amino were observed when monkeys were treated with a single oral groups at positions 1 and 3 of the lead molecule WR227825 are dose (3 mg/kg) of 2a or 3a. No adverse effects regarding anessential for the inhibition of DHFR (15). Surprisingly, comorexia, vomiting, diarrhea, or behavior changes were observed pound 4 showed potent antimalarial activity in animal studies. during a 28-day observation period. No significant changes in It cured 100% of mice infected with P. berghei at an oral dose
